Trial reportThe international journal of neuropsychopharmacology2014
Effects of oxytocin on attention to emotional faces in healthy volunteers and highly socially anxious males.
Erratum issuedOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in The international journal of neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Pharmacotherapy for social anxiety disorder (SAnD).The Cochrane database of systematic reviews · 2017Pooled it
- Acute effects of oxytocin in music performance anxiety: a crossover, randomized, placebo-controlled trial.Psychopharmacology · 2020Trial
- Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.Translational psychiatry · 2017Trial
- Restoring effects of oxytocin on the attentional preference for faces in autism.Translational psychiatry · 2017Trial
- Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment.Translational psychiatry · 2015Trial
- How does oxytocin modulate human behavior?Molecular psychiatry · 2025Review
- The Multifaceted Role of Oxytocinergic System andGlobal medical genetics · 2024Review
- Perinatal high-fat diet exposure alters oxytocin and corticotropin releasing factor inputs onto vagal neurocircuits controlling gastric motility.The Journal of physiology · 2023Article
- A Systematic Review of the Role of Oxytocin, Cortisol, and Testosterone in Facial Emotional Processing.Biology · 2021Review
- Neurochemistry of Visual Attention.Frontiers in neuroscience · 2021Review
- Impact of intranasal oxytocin on interoceptive accuracy in alcohol users: an attentional mechanism?Social cognitive and affective neuroscience · 2018Article
- Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults.Cannabis and cannabinoid research · 2017Article
- Canine companionship is associated with modification of attentional bias in posttraumatic stress disorder.PloS one · 2017Article
- Neuropeptide Regulation of Social Attachment: The Prairie Vole Model.Comprehensive Physiology · 2016Review
- Effects of chronic oxytocin on attention to dynamic facial expressions in infant macaques.Psychoneuroendocrinology · 2016Article
- Low Fasting Oxytocin Levels Are Associated With Psychopathology in Anorexia Nervosa in Partial Recovery.The Journal of clinical psychiatry · 2016Article
- Social-Emotional Inhibition of Return in Children with Autism Spectrum Disorder Versus Typical Development.Journal of autism and developmental disorders · 2016Article
- Oxytocin in the socioemotional brain: implications for psychiatric disorders.Dialogues in clinical neuroscience · 2015Review
Corrections and comments
- Erratum issuedErratum.2016
Authors and funding
10 authors at 4 institutions in 2 countries.
Rebecca Clark-ElfordDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian). rjc84@cam.ac.uk.
Pradeep J NathanDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Bonnie AuyeungDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Karin MoggDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Brendan P BradleyDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Akeem SuleDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Ulrich MüllerDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Robert B DudasDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Barbara J SahakianDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
Simon Baron-CohenDepartment of Psychiatry, University of Cambridge, UK (Mrs Clark Elford, Professors Nathan, Mogg, Bradley, Sahakian,and Baron-Cohen, and Drs Auyeung, Sule, Muller, and Dudas ); Cambridge Cognition Ltd, Cambridge, UK (Dr Nathan); School of Psychology and Psychiatry, Monash University, Australia (Dr Nathan); Autism Research Centre, Department of Psychiatry, University of Cambridge, UK (Drs Auyeung and Baron-Cohen); Department of Psychology, University of Edinburgh, UK (Dr Auyeung); South Essex NHS Partnership Trust, UK (Dr Sule); Psychology, University of Southampton, UK (Drs Mogg and Bradley); Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), UK (Drs Müller, Dudas, and Baron-Cohen); MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge (Dr Sahakian).
University of Edinburgh · GBSouth Essex Partnership University Foundation NHS Trust · GBCambridgeshire and Peterborough NHS Foundation Trust · GBMonash University · AU
Funding
Biotechnology and Biological Sciences Research CouncilMedical Research Council G0600977
Abstract
backgroundEvidence suggests that individuals with social anxiety demonstrate vigilance to social threat, whilst the peptide hormone oxytocin is widely accepted as supporting affiliative behaviour in humans.
methodsThis study investigated whether oxytocin can affect attentional bias in social anxiety. In a double-blind, randomized, placebo-controlled, within-group study design, 26 healthy and 16 highly socially anxious (HSA) male volunteers (within the HSA group, 10 were diagnosed with generalized social anxiety disorder) were administered 24 IU of oxytocin or placebo to investigate attentional processing in social anxiety. Attentional bias was assessed using the dot-probe paradigm with angry, fearful, happy and neutral face stimuli.
resultsIn the baseline placebo condition, the HSA group showed greater attentional bias for emotional faces than healthy individuals. Oxytocin reduced the difference between HSA and non-socially anxious individuals in attentional bias for emotional faces. Moreover, it appeared to normalize attentional bias in HSA individuals to levels seen in the healthy population in the baseline condition. The biological mechanisms by which oxytocin may be exerting these effects are discussed.
conclusionsThese results, coupled with previous research, could indicate a potential therapeutic use of this hormone in treatment for social anxiety.
Indexed as
AdolescentAdultAnxiety DisordersAttentionDouble-Blind MethodEmotionsFaceFacial ExpressionHumansMaleMiddle AgedNeuropsychological TestsOxytocinPattern Recognition, VisualPhotic StimulationPsychotropic DrugsOxytocinPsychotropic Drugsattentionattentional biasemotionfacial expressionoxytocinsocial anxiety
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.